Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulvestrant in Premenopausal Women With HR+ Breast Cancer
NCT00146601Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jun 2004
- Primary completion
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fulvestrant in breast cancer, sponsored by Dana-Farber Cancer Institute. Primary endpoints: Clinical Benefit Rate and Response Rate. Started Jun 2004; status: completed.
02
Drugs
fulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00146601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00146601.